Join

Compare · NVS vs ZIVO

NVS vs ZIVO

Side-by-side comparison of Novartis AG (NVS) and Zivo Bioscience Inc. (ZIVO): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NVS and ZIVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVS is the larger of the two at $279.39B, about 11407.9x ZIVO ($24.5M).
  • NVS has more recent analyst coverage (25 ratings vs 1 for ZIVO).
MetricNVSZIVO
Company
Novartis AG
Zivo Bioscience Inc.
Price
$148.72+1.52%
$1.26+8.12%
Market cap
$279.39B
$24.5M
1M return
+1.86%
-
1Y return
+26.00%
-
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
News (4w)
0
0
Recent ratings
25
1
NVS

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

ZIVO

Zivo Bioscience Inc.

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is based in Keego Harbor, Michigan.